Tuesday, February 9, 2016

Business

AstraZeneca new CEO gets started but profits fall again

AstraZeneca, which is based in the United Kingdom but has a big operation in Wilmington, said its third-quarter profit dropped more than 50 percent, indicating the challenge ahead for new chief executive officer Pascal Soriot.

AstraZeneca new CEO gets started but profits fall again

0 comments

AstraZeneca, which is based in the United Kingdom but has a big operation in Wilmington, said its third-quarter profit dropped more than 50 percent, indicating the challenge ahead for new chief executive officer Pascal Soriot.

"We are facing patent challenges for some products, but we have growth platforms," Soriot said in a conference call.

Soriot departed Roche and stepped into his new job on Oct. 1. He has said he will explain his grand plan for the company in the coming months.

The biggest component in the company's earning slide is the end of patent exclusivity of its blockbuster antipsychotic drug Seroquel. The patent expiration opened the market to generic competitors.

More coverage
More 'PhillyPharma' posts

Sales of Seroquel IR were $1.034 billion in the third quarter of 2011, but fell to $169 million in the same period of 2012.

On August 8, AstraZeneca completed most of what will end up being a $7 billion deal with Bristol-Myers Squibb to acquire Amylin's diabetes products.

The company has cut its workforce in the last few years, with some of the cuts hitting AstraZeneca facilities in Wilmington and Newark, Del.

In its Thursday statement, the company said it took $253 million in restructuring charges in the third quarter and most of the $2.1 billion in charges will be taken in 2012.

Soriot was not specific, but said "business development," could be a way to improve the pipeline of drugs.

Bernstein analyst Tim Anderson has said that an acquisition might be necessary and Shire, Plc., is one possibility. Shire is also based in the UK, but its U.S. headquarters is in Chesterbrook.

 

Staff Writer
0 comments
We encourage respectful comments but reserve the right to delete anything that doesn't contribute to an engaging dialogue.
Help us moderate this thread by flagging comments that violate our guidelines.

Comment policy:

Philly.com comments are intended to be civil, friendly conversations. Please treat other participants with respect and in a way that you would want to be treated. You are responsible for what you say. And please, stay on topic. If you see an objectionable post, please report it to us using the "Report Abuse" option.

Please note that comments are monitored by Philly.com staff. We reserve the right at all times to remove any information or materials that are unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane, indecent or otherwise objectionable. Personal attacks, especially on other participants, are not permitted. We reserve the right to permanently block any user who violates these terms and conditions.

Additionally comments that are long, have multiple paragraph breaks, include code, or include hyperlinks may not be posted.

Read 0 comments
 
comments powered by Disqus
About this blog
David Sell blogs about the region's pharmaceutical industry. Follow him on Facebook.

Portions of this blog may also be found in the Inquirer's Sunday Health Section.

Reach David at dsell@phillynews.com or 215-854-4506.

David Sell Staff Writer
Also on Philly.com:
letter icon Newsletter